Abstract. Arsenic trioxide (ATO; As 2 O 3 ) induces cell death in various types of cancer cells including lung cancer via increasing reactive oxygen species (ROS) and regulating mitogen-activated protein kinase (MAPK) signaling cascades. However, little is known about the relationship between ATO and MAPK signaling in normal lung cells. Here, we investigated the effects of MAPK inhibitors and siRNAs on ATO-treated human pulmonary fibroblast (HPF) cells in relation to cell growth, cell death, ROS and glutathione (GSH) levels. ATO induced cell growth inhibition and death in HPF cells and it increased ROS levels including O 2
Introduction
Reactive oxygen species (ROS) include hydrogen peroxide (H 2 O 2 ), the superoxide anion (O 2 •-) and the hydroxyl radical (
• OH), which are implicated in many cellular functions such as differentiation, cell proliferation and cell death. They are mainly generated as by-products of mitochondrial respiration or are specifically produced by oxidases, such as nicotine adenine diphosphate (NADPH) oxidase and xanthine oxidase (1) . The principal metabolic pathways include superoxide dismutases (SODs), which metabolize O 2 •-to H 2 O 2 (2) . Further metabolism by catalase or glutathione (GSH) peroxidase (GPX), yields O 2 and H 2 O (3). Oxidative stress may result from either overproduction of ROS or accumulation of it.
The mitogen-activated protein kinases (MAPKs) are a family of proteins that transfer signals from the cell membrane to the nucleus in response to different upstream stimuli. Three major groups of MAPKs exist: the extracellular signal regulated kinase (ERK1/2), the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 (4) . MAPK signaling pathways are involved in cell proliferation, differentiation and cell death (5) . Numerous studies suggest that JNK and p38 are activated by ROS, leading to apoptosis (6) (7) (8) . ROS can also regulate the activation of the ERK and ERK-activating kinase (MEK) (9) . In most instances, MEK-ERK signaling makes a contribution to a pro-survival function rather than a proapoptotic effect (10) .
Arsenic trioxide (ATO; As 2 O 3 ) has long been used as a therapeutic agent for severe diseases including leukemia in East Asia (11) . Recently, the antiproliferative effect of ATO has been implicated in a variety of hematological malignancies, especially acute promyelocytic leukemia (APL) (12, 13) . In addition, there is accumulating evidence that ATO induces apoptotic cell death in renal (14) , cervical (15) and gastric cancer cells (16) . ATO as a mitochondrial poison can induce the collapse of the mitochondrial transmembrane potential (MMP; ∆Ψ m ) and, as such, it generates high amounts of ROS (17) . ATO also increases ROS levels via the activation of NADPH oxidase (18) or the inhibition of GPX and thioredoxin reductase (TXNR) (19, 20) . These phenomena can trigger the apoptosis of target cells. In addition, it has been reported that the intracellular GSH content has a decisive effect on ATO-induced apoptosis (21, 22) . Moreover, the inhibition of MEK/ERK signaling enhances cell death in ATO-treated myeloma and leukemia cells (23) (24) (25) . ATO-induced apoptosis in cancer cells is related to the activation of JNK (24, (26) (27) (28) (29) (30) and/or p38 (27, 28) . On the other hand, it is also reported that blockage of JNK pathway increases ATO-induced apoptosis in human keratinocytes (31) and the inhibition of p38 signaling enhances myeloma cell death by ATO (32) .
We recently demonstrated that ATO inhibits the growth of Calu-6 lung cancer cells by inducing cell cycle arrest and apoptosis (33) and MAPK (MEK, JNK and p38) inhibitors slightly intensify cell death in ATO-treated Calu-6 cells (34). However, little is known about the relationship between ATO and MAPK signaling in normal lung cells in relation to ROS. Because we observed that ATO induces the growth inhibition and death in human pulmonary fibroblast (HPF) cells (35) , in the present study we investigated the effects of MAPK inhibitors or siRNAs on cell growth, cell death, ROS and GSH levels in ATO-treated HPF cells.
Materials and methods
Cell culture. Human pulmonary fibroblast (HPF) cells obtained from PromoCell GmbH (Heidelberg, Germany) were maintained in a humidified incubator containing 5% CO 2 at 37˚C. HPF cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Gibco-BRL, Grand Island, NY). HPF cells were used between passages four and eight.
Reagents. ATO was purchased from Sigma-Aldrich Chemical Company (St. Louis, MO) and was dissolved in 1.65 M NaOH at 100 mM as a stock solution. The MEK (PD98059), JNK (SP600125) and p38 inhibitors (SB203580) obtained from Calbiochem (San Diego, CA) were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich Chemical Company). Cells were pretreated with each MAPK inhibitor for 1 h before ATO treatment. Based on the previous experiment (36), 10 µM of each MAPK inhibitor was used as an optimal dose in this experiment. DMSO (0.2%) was used as a control vehicle and it did not alter cell growth or death.
Cell growth assays. Cell growth changes in drug-treated cells were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich Chemical Company) assay as previously described (12) . In brief, 3x10 4 cells/well were seeded in 96-well microtiter plates (Nunc, Roskilde, Denmark). After exposure to 50 µM ATO in the presence or absence of a given MAPK inhibitor or MAPK-related siRNA duplex for 24 h, 20 µl of MTT solution [2 mg/ml in phosphate-buffered saline (PBS)] were added to each well of the 96-well plates. The plates were incubated for 4 additional hours at 37˚C. Media in plates were withdrawn by pipetting and 200 µl of DMSO was added to each well to solubilize the formazan crystals. Optical density was measured at 570 nm using a microplate reader (SpectraMAX 340, Molecular Devices Co., Sunnyvale, CA).
Annexin-V/PI staining for cell death detection. Apoptosis was determined by staining cells with Annexin-V-fluorescein isothiocyanate (FITC, Ex/Em=488 nm/519 nm; Invitrogen Molecular Probes, Eugene, OR) and propidium iodide (PI, Ex/ Em=488 nm/617 nm; Sigma-Aldrich Chemical Company). In brief, 1x10 6 cells in 60-mm culture dishes (Nunc) were incubated with 50 µM ATO in the presence or absence of a given MAPK inhibitor or MAPK-related siRNA duplex for 24 h. Cells were washed twice with cold PBS and then resuspended in 500 µl of binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) at a concentration of 1x10 6 cells/ml. Annexin-V-FITC (5 µl) and/or PI (1 µg/ml) were then added to these cells, which were analyzed with a FACStar flow cytometer (Becton-Dickinson, Franklin Lakes, NJ).
Measurement of mitochondrial membrane potential [MMP (∆Ψ m )]
. MMP (∆Ψ m ) levels were measured using a rhodamine 123 fluorescent dye (Sigma-Aldrich Chemical Company; Ex/ Em=485 nm/535 nm) as previously described (37) . In brief, 1x10 6 
Detection of intracellular ROS and O 2
•-levels. Intracellular ROS were detected by means of an oxidation-sensitive fluorescent probe dye, 2',7'-dichlorodihydrofluorescein diacetate (H 2 DCFDA, Ex/Em=495 nm/529 nm; Invitrogen Molecular Probes) as previously described (38) . H 2 DCFDA is poorly selective for superoxide anion radical (O 2 •-). In contrast, dihydroethidium (DHE, Ex/Em=518 nm/605 nm; Invitrogen Molecular Probes) is a fluorogenic probe that is highly selective for O 2 •-among the ROS, as previously described (38) .
•-levels were detected using the MitoSOX™ Red mitochondrial O 2 •-indicator (Ex/Em=510 nm/580 nm; Invitrogen Molecular Probes) as previously described (38) . In brief, 1x10 6 cells in 60-mm culture dish (Nunc) were incubated with 50 µM ATO in the presence or absence of a given MAPK inhibitor or MAPK-related siRNA duplex for 24 h. Cells were then washed in PBS and incubated with 20 µM H 2 DCFDA, 20 µM DHE or 5 µM MitoSOX Red at 37˚C for 30 min. DCF, DHE and MitoSOX Red fluorescence intensities were measured using a FACStar flow cytometer (Becton-Dickinson). ROS and O 2 •-levels were expressed as mean fluorescence intensity (MFI), which was calculated by the CellQuest software (Becton-Dickinson).
Detection of intracellular glutathione (GSH) levels. Cellular GSH levels were analyzed using a 5-chloromethylfluorescein diacetate dye (CMFDA, Ex/Em=522 nm/595 nm; Invitrogen Molecular Probes) as previously described (38) . In brief, 1x10 6 cells in 60-mm culture dishes (Nunc) were incubated with 50 µM ATO in the presence or absence of a given MAPK inhibitor or MAPK-related siRNA duplex for 24 h. Cells were then washed with PBS and incubated with 5 µM CMFDA at 37˚C for 30 min. The CMF fluorescence intensity was determined using a FACStar flow cytometer (Becton-Dickinson). Negative CMF-stained (GSH-depleted) cells were expressed as the percent of (-) CMF cells.
Transfection of cells with MAPK-related siRNAs.
Gene silencing of ERK, JNK and p38 was performed as previously described (39) . 
Statistical analysis.
The results represent the mean of at least three independent experiments (mean ± SD). The data were analyzed using Instat software (GraphPad Software Inc., San Diego, CA). The Student's t-test or one-way analysis of variance (ANOVA) with post hoc analysis using Tukey's multiple comparison test was used for parametric data. Statistical significance was defined as P<0.05.
Results

Effects of MAPK inhibitors on cell growth and death in ATO-treated HPF cells.
We examined the effect of MAPK inhibitors on the growth of ATO-treated HPF cells. For this experiment, 50 µM ATO was chosen as a suitable dose to examine the extent of cell growth inhibition and death with or without a given MAPK inhibitor. Based on the MTT assay, 50 µM ATO inhibited the growth of HPF cells by about 65% at 24 h (Fig. 1) . None of MAPK inhibitors affected the growth of ATO-treated HPF cells (Fig. 1) . The p38 inhibitor alone increased the growth of HPF control cells (Fig. 1) . ATO significantly induced cell death in HPF cells, as evidenced by Annexin-V-FITC staining ( Fig. 2A and C) . None of the MAPK inhibitors changed the number of Annexin-V staining cells in ATO-treated or -untreated HPF cells ( Fig. 2A and C) . Furthermore, ATO induced the loss of MMP (∆Ψ m ) in HPF cells (Fig. 2B and D) . All the MAPK inhibitors seemed to enhance the loss of MMP (∆Ψ m ) in ATO-treated HPF cells and this effect was statistically significant in the p38 inhibitortreated group (Fig. 2B and D) .
Effects of MAPK inhibitors on ROS and GSH levels in
ATO-treated HPF cells. Next, we determined whether ROS and GSH levels in ATO-treated HPF cells were changed by each MAPK inhibitor. The ROS (DCF) levels were increased in ATO-treated HPF cells (Fig. 3A) . While the MEK inhibitor slightly attenuated ROS levels in ATO-treated HPF cells, the p38 inhibitor seemed to increase the ROS levels (Fig. 3A) . DHE level reflecting intracellular O 2 •-was also increased in ATO-treated HPF cells (Fig. 3B) . The MEK inhibitor seemed to decrease O 2 •-level in ATO-treated HPF cells whereas the p38 inhibitor augmented the O 2 •-level (Fig. 3B ). p38 inhibitor alone increased ROS levels including O 2 •-in HPF control cells (Fig. 3A and B) . Furthermore, MitoSOX Red fluorescence levels, which specifically indicate O 2 •-levels in the mitochondria, were strongly increased in ATO-treated HPF cells (Fig. 3C) . The MEK inhibitor decreased mitochondrial O 2 •-level in ATO-treated HPF cells whereas JNK and p38 inhibitors increased the O 2 •-level (Fig. 3C) . The JNK inhibitor decreased mitochondrial O 2 •-levels in control HPF cells (Fig. 3C) . In relation to GSH levels, ATO increased the number of GSH depleted cells in HPF cells (Fig. 3D) . None of the MAPK inhibitors altered GSH depleted cell number in ATO-treated and -untreated HPF cells (Fig. 3D) .
Effects of MAPK-related siRNAs on cell growth and death in ATO-treated HPF cells.
Furthermore, it was determined whether MAPK (ERK, JNK and p38)-related siRNAs changed cell growth and death levels in ATO-treated HPF cells. As shown in Fig. 4A , 50 µM ATO decreased HPF cell growth about 20% as compared with control siRNA-treated HPF cells. While ERK siRNA did not affect the growth in ATO-treated HPF cells, JNK and p38 siRNAs intensified the growth inhibition by ATO (Fig. 4A) . Treatment with 50 µM ATO increased the proportion of Annexin-V-stained cells by at most 10% as compared with control siRNA-treated HPF cells (Fig. 4B) . Probably, the siRNA knockdown system with Lipofectamine 2000 seemed to attenuate the biological activity of ATO. All the MAPK siRNAs did not affect the percentages of Annexin-V-stained cells in HPF control cells for 48 h (Fig. 4B) . JNK and p38 siRNAs enhanced Annexin-V-stained cell number in ATO-treated HPF cells (Fig. 4B) . In relation (Fig. 4C) .
Effects of MAPK-related siRNAs on ROS and GSH levels in ATO-treated HPF cells. ATO did not increase ROS (DCF)
levels in control siRNA-treated HPF cells at 24 h but it slightly increased O 2
•-level in these cells (Fig. 5A and B) . ATO strongly increased mitochondrial O 2 •-levels (Fig. 5C) . None of the MAPK siRNAs significantly altered ROS levels including O 2
•-in HPF cells treated for 48 h, but had a tendency to decrease them (Fig. 5) . ERK siRNA did not change ROS (DCF) levels in ATO-treated HPF cells (Fig. 5A) , but it slightly increased O 2 •-levels including mitochondrial O 2 •-in these cells ( Fig. 5B  and C) . Both JNK and p38 siRNAs clearly increased ROS levels including O 2 •-in ATO-treated HPF cells (Fig. 5) . Moreover, ATO increased the number of GSH-depleted cells by ~5% as compared with the control siRNA-treated HPF cells (Fig. 6) . None of the MAPK siRNAs affected GSH depletion in HPF control cells after 48 h (Fig. 6 ). JNK and p38 siRNAs increased GSH depleted cell number in ATO-treated HPF cells (Fig. 6) .
Discussion
In the present study, we demonstrated the effects of MAPK inhibitors or siRNAs on cell growth, cell death, ROS and GSH levels in ATO-treated HPF cells. ATO can induce the failure of MMP (∆Ψ m ), consequently generating high amounts of ROS (17, 40) . It also increases ROS levels via the activation of NADPH oxidase (18) or the inhibition of GPX and TXNR (19, 20) . These phenomena can lead to apoptosis in target cells. According to our current results, ATO increased ROS levels including O 2 •-and induced growth inhibition and death in HPF cells. Furthermore, the loss of MMP (∆Ψ m ) and mitochondrial O 2 •-levels was strongly increased in ATO-treated HPF cells, implying the possibility that the production of ROS in ATO-treated HPF cells mainly resulted from the disruption of mitochondria.
ERK activation has a pro-survival function rather than pro-apoptotic effects (10) . In fact, the inhibition of MEK/ERK signaling enhances cell death in ATO-treated myeloma and leukemia cells (23) (24) (25) . On the other hand, the MEK inhibitor intensifies growth inhibition and death in the ATO-treated Calu-6 lung cancer cells (34) . According to our result, the MEK inhibitor, which presumably decreased ERK activity, did not significantly affect HPF cell growth inhibition and death by ATO. The MEK inhibitor alone did not change HPF growth and death. Furthermore, ERK siRNA did not change HPF cell growth and death by ATO. These results suggested that the inhibition of ERK signaling is not tightly related to cell growth inhibition and death in ATO-treated or -untreated HPF cells. In addition, the MEK inhibitor seemed to decrease ROS levels,
•-in ATO-treated HPF cells whereas ERK siRNA slightly increased O 2 •-level in these cells. The MEK inhibitor and ERK siRNA are likely to differently influence redox states in HPF cells without the alteration of cell growth and death.
It has been reported that ATO-induced apoptosis in cancer cells is related to the activation of JNK (24, (26) (27) (28) (29) (30) and/or p38 (27, 28) . In contrast, it is also reported that the blockage of the JNK pathway increases ATO-induced apoptosis in human keratinocytes (31) and that of p38 signaling enhances myeloma cell death by ATO (32) . Similarly, we recently demonstrated that JNK and p38 inhibitors augment growth inhibition and death in the ATO-treated Calu-6 cells (34) . According to our current results, both JNK and p38 inhibitors did not affect cell growth and death in ATO-treated HPF cells whereas these siRNAs augmented cell growth inhibition and death in these cells. The p38 inhibitor alone increased HPF control cell growth but its siRNA did not alter the growth. Therefore, different ways in the prevention of JNK and p38 signaling by their inhibitors and siRNAs differently affect cell growth and death in ATO-treated or -untreated HPF cells. These results demonstrate that a pro-survival or pro-apoptotic effect of JNK and p38 signaling in ATO-treated cells is dependent of cell types and/or ways used to block their signaling. Moreover, both inhibitors increased the loss of MMP (∆Ψ m ) in ATO-treated HPF cells without a convincible increase in cell death whereas both siRNAs did not affect the loss in these cells, implying that MMP (∆Ψ m ) loss in HPF cells was not tightly correlated with their cell death.
The JNK and p38 inhibitors seemed to increased ROS levels including mitochondrial O 2 •-levels in ATO-treated HPF cells. Especially, the p38 inhibitor significantly increased ROS levels in these cells and HPF control cells without influencing the cell death level. On the other hand, JNK or p38 siRNA increased ROS levels in ATO-treated HPF cells, accompanied by an increase in HPF cell death. These results suggest that the changes of ROS levels in ATO-treated or -untreated HPF cells by the JNK and p38 inhibitors or siRNAs are not tightly but at least partially related to HPF cell death. In addition, JNK and p38 inhibitors and their siRNAs differently influence ROS levels in these cells. The intracellular GSH content has a decisive effect on ATO-induced apoptosis (21, 22) . As expected, ATO increased GSH depleted cell number in HPF cells. The MAPK inhibitors did not significantly alter the number of GSH-depleted HPF cells after ATO treatment. JNK and p38 siRNAs showed an enhancement in ATO-induced HPF cell death and increased the GSH-depleted cell number in these cells.
In conclusion, MAPK inhibitors altered ROS levels, but did not affect growth inhibition and death in ATO-treated HPF cells. JNK and p38 siRNAs showing an increase in ROS levels and GSH depletion in ATO-treated HPF cells augmented HPF cell growth inhibition and death. Our present data provide useful information to understand the toxicological effects of ATO on normal lung cells in relation to MAPK signaling and ROS levels.
